Aprajita Jagpal is a Rheumatology/Immunology physician. OpenAlex indexes 14 publications with 233 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9555 SW Barnes Rd Ste 150
Portland, OR 972256691
Telephone
503-297-3384Provider last certified this registry record 20 Feb 2025.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20251 payment
- Janssen Biotech, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
64.6%TNF inhibitor30.3%Golimumab83%Infliximab16%Enbrel Sureclick0%Humira(Cf) Pen0%Part D + Part B<11 patientsInterleukin-6 Receptor Antagonist28.4%Tocilizumab100%Part B, office-administered≥11 patients+ 3 more classes in this area
Musculoskeletal
33.7%Other drugs affecting bone structure and mineralization27.1%Romosozumab-aqqg100%Part B, office-administered≥14 patientsRANK Ligand Inhibitor6%Denosumab100%Part B, office-administered≥30 patients+ 3 more classes in this area
Metabolism & gastrointestinal
1.3%Corticosteroid0.9%Prednisone100%Part D≥98 patientsAntidiarrheal microorganisms0.3%Folic Acid100%Part D≥25 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treatment Guidelines in Rheumatoid Arthritis—Optimizing the Best of Both Worlds
Current Treatment Options in Rheumatology
2020 - Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)
Baylor University Medical Center Proceedings
2019
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”